ERBB2 and breast cancer: In fact, the present findings are of particular interest in patients with HR-positive/ERBB2-negative cN-positive BC, with 91 of 151 patients (60%) undergoing adjuvant chemotherapy when ALND is used, compared with 81 of 145 patients (56%) without ALND.